scholarly journals Combined Effect of Blood Cadmium and Lead Levels on Testosterone Level in Korean Men

2016 ◽  
Vol 9 (1) ◽  
pp. 166-166
Author(s):  
S. Lee ◽  
◽  
D. Cho ◽  
K. Kim ◽  
N. Joo ◽  
...  
Keyword(s):  
Testosterone Level ◽  
Reference Group ◽  
Smoking Status ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Health And Nutrition ◽  
Blood Cadmium ◽  
Lead Levels ◽  
Cadmium And Lead ◽  
Low Serum

Objective: This study was designed to investigate the combined effects of cadmium (Cd) and lead (Pb) on testosterone level in men. Design and Method: The heavy metal dataset of the Korean National Health and Nutrition Examination Survey (KNHANES) IV and V (2008 - 2012) was analyzed. Results: The serum testosterone level was significantly associated with the logtransformed blood Cd and Pb levels. For the highest quartile of Cd and Pb, the odds ratio (OR) of the risk of low serum testosterone level compared with the lowest quartile was 6.890 (Cd, 95% CI: 4.59-10.70) and 3.117 (Pb, 95% CI: 2.03-4.39) after adjusting for confounders (age, body mass index, smoking status, diabetes and alcohol intake), respectively. The adjusted OR of the risk of low serum testosterone level in the 4th quartile of both Cd and Pb was 13.7 (95% CI: 9.0-19.5) compared with the reference group (1st and 2nd quartile of Cd and Pb). Conclusions: This study is the most comprehensive investigation to date regarding the association between heavy metals and sex hormones in males.

Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17545-e17545
Author(s):  
Maysa Tamara Silveira Vilbert ◽  
Marcelle Goldner Cesca ◽  
Natasha Carvalho Pandolfi ◽  
Vinicius Fernando Calsavara ◽  
Bruno Cezar de Mendonça Uchôa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Testosterone Level ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Testosterone Levels ◽  
Castration Resistant ◽  
Low Serum

e17545 Background: Androgen receptor-targeted agents Abiraterone and Enzalutamide (Abi/Ez) prolonged overall survival in metastatic castration resistant prostate cancer (mCRPC). Patients with very-low serum testosterone levels seem to have less benefit from these therapies as well as more aggressive prostate cancer. Methods: A retrospective observational cohort study was conducted to evaluate whether a serum testosterone measured at time of start first-line therapy with Abi/Ez is related to overall survival (OS) and time-to-treatment failure (TTF) in mCRPC patients. Kaplan-Meier survival estimates and Cox-regression models were used for time-to-event analyses. The best cut-off for testosterone was defined using Log-rank statistics (Lausen and Schumacher). X² test and Mann-Whitney U-test were applied to compare categorical and continuous variables, respectively. Logistic regression was used to assess characteristics related to serum testosterone levels. Statistical significance was fixed at 0.05. Results: From May 2012 to February 2017, 100 patients were assessed. Median follow-up was 27.8 months (range 2.23 to 68.26). Pts with a high testosterone level ( > 28.2; n = 20) achieved a significantly higher OS (median 66.0 vs 31.9 mo, testosterone > 28.2 HR: 0.206, 95% CI 0.074 to 0.571, p = 0.002) and TTF (median 30.6 vs 11.8 mo, testosterone > 28.2 HR: 0.408, 95%CI 0.219 to 0.762, p = 0.005) than pts with a low serum testosterone level ( < 28.2; n = 80), regardless of receiving therapy with either Abi (n = 69) or Ez (n = 31). Pts with a higher testosterone level were younger (median 67.7 vs 73.6 years; p = 0.026), had a higher body mass index (BMI) (28.5 vs 25.9, p = 0.023) and a lower PSA at start Abi/Ez (12 vs 26, p = 0.031) than pts with lower values. Age (OR 0.93, 95%CI 0.8 to 0.9, p = 0.021), BMI (OR 1.21, 95%CI 1.1 to 1.4, p = 0.006) and baseline PSA (OR 1.2, 95%CI 1.03 to 1.4, p = 0.020) were significantly associated with testosterone > 28.2. After 4 months of Abi/Ez treatment, PSA decrease > 50% of baseline was seen more frequently in high testosterone levels group than in low testosterone levels pts (90% vs 57.5% of pts, respectively, p = 0.007). Conclusions: Pts with high levels of testosterone ( > 28.2) achieved a better OS and TTF when treated with Abi/Ez in first-line mCRPC than those with low levels. Testosterone can be considered a prognostic and predictive biomarker in this scenario, and could be used in treatment decision for this population.

scholarly journals The association between serum testosterone levels and metabolic syndrome among women

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Junxiao Liang ◽  
Qiaohua Peng ◽  
Xinyun Yang ◽  
Chunbo Yang
Keyword(s):  
Metabolic Syndrome ◽  
Testosterone Level ◽  
Menopausal Status ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Total Serum ◽  
Female Population ◽  
Logistic Regression Models ◽  
Health And Nutrition ◽  
The Relationship

Abstract Background This study aimed to investigate the relationship between total serum testosterone level (TT) and metabolic syndrome (MetS) among adult female population. Subgroup analysis further stratified the population by menopausal status to address the potential hormonal difference in postmenopausal women. Methods A total of 1966 participants from the National Health and Nutrition Examination Survey (NHANES) 2011–2012 cycle was included for analysis in this study. MetS was defined based on the National Cholesterol Education Program Adult Treatment Panel III guidelines. Serum TT was collected during the physical examination of the NHANES program and divided into quartiles (Q) in this analysis. Menopausal status was determined based on NHANES Reproductive Health Questionnaire. Logistic regression models were applied for analysis. Results The odds of MetS in Q2: 12.99–19.38 ng/mL (OR = 0.641, 95%CI 0.493–0.835, P < 0.01), Q3: 19.39–28.38 ng/mL (OR = 0.476, 95%CI 0.362–0.626, P < 0.001), and Q4: ≥28.40 ng/mL (OR = 0.390, 95%CI 0.294–0.517, P < 0.001) were statistically lower compared to the reference Q1: <12.99 ng/mL. For the postmenopausal group, a significantly lower odds of MetS was observed in the Q2 (OR = 0.689, 95%CI 0.486–0.977, P < 0.05) and Q4 (OR = 0.606, 95%CI 0.399–0.922, P < 0.05), while the odds of Q3 (OR = 0.439, 95%CI 0.248–0.779, P < 0.01) and Q4 (OR = 0.464, 95%CI 0.261–0.825, P < 0.01) were significantly lower than the reference Q1 in the premenopausal group. Conclusions Elevated TT levels are associated with incremental reductions in the odds of metabolic syndrome among adult females. Although, serum testosterone level is associated with the occurrence of metabolic syndrome in both the postmenopausal and the premenopausal group, the patterns of the relationship are different.

Low Serum Testosterone Level Predisposes to Artificial Urinary Sphincter Cuff Erosion

Urology ◽  
2016 ◽  
Vol 97 ◽  
pp. 245-249 ◽  
Author(s):  
Matthias D. Hofer ◽  
Allen F. Morey ◽  
Kunj Sheth ◽  
Timothy J. Tausch ◽  
Jordan Siegel ◽  
...  
Keyword(s):  
Testosterone Level ◽  
Serum Testosterone ◽  
Artificial Urinary Sphincter ◽  
Serum Testosterone Level ◽  
Urinary Sphincter ◽  
Low Serum

Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer

Urology ◽  
2005 ◽  
Vol 65 (6) ◽  
pp. 1141-1145 ◽  
Author(s):  
Georg Schatzl ◽  
Michael Marberger ◽  
Mesut Remzi ◽  
Petra Grösser ◽  
Julia Unterlechner ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Testosterone Level ◽  
Specific Antigen ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
High Grade ◽  
Antigen Gene ◽  
Low Serum

MP51-12 LOW SERUM TESTOSTERONE LEVEL IS ASSOCIATED WITH BRACHIAL-ANKLE PULSE WAVE VELOCITY IN PATIENTS WITH SYMPTOM OF LATEONSET HYPOGONADISM

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Akira Tsujimura ◽  
Shin-ichi Hisasue ◽  
Yoshiaki Kumamoto ◽  
Kazuhiro Kobayashi ◽  
Shigeo Horie
Keyword(s):  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Testosterone Level ◽  
Pulse Wave ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Low Serum

scholarly journals Serum Testosterone Level and Response to Androgen Deficiency in Aging Males (Adam) Questionnaire in Chronic Kidney Disease (CKD) - A Single Center Study

2017 ◽  
Vol 26 (1) ◽  
pp. 73-78
Author(s):  
Eusha Ahmad Fidalillah Ansary ◽  
Md Nazrul Islam ◽  
Md Bellal Hossain ◽  
Md Abdullah Al Mamun ◽  
Md Faruq Amin Talukder ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Testosterone Level ◽  
Healthy Subjects ◽  
Early Recognition ◽  
Serum Testosterone ◽  
Serum Testosterone Level ◽  
Medical College ◽  
Ckd Stage ◽  
Low Serum

Introduction: Abnormalities of serum testosterone level in males are observed in chronic kidney disease (CKD) patients. Erectile dysfunction, decreased libido, infertility in chronic kidney disease (CKD) patients is associated with low serum testosterone. So this study of CKD patients help early recognition of these adverse conditions associated with low serum testosterone level and thus specific actions may be taken earlier.Objective: To evaluate the serum testosterone level and the response of ADAM questionnaire in males with different stages of chronic kidney disease (CKD).Method: This cross sectional study was done From January to December, 2014 in the Department of Nephrology, Dhaka Medical College Hospital. A total of 90 diagnosed cases of adult male with different stages of CKD (CKD stage 3, 4, 5 and 5D) patients along with age matched 88 healthy individuals were included. Every subject was provided the Bangla version of ADAM questionnaire. Serum Testosterone was done by 125I-testosterone RIA system. P values <0.05 was considered as statistically significant.Result: Mean S. testosterone was found 4.29±1.9 ng/ml in CKD patients (group A) and 9.15±1.2 ng/ml in healthy subjects (group B). The mean S. Testosterone difference was statistically significant (p<0.05) between two groups. It was observed that positive response to ADAM questionnaire was found 11.4% in healthy subjects, 10.1% in CKD stage 3, 54.5% in CKD stage 4, 100% in CKD stage 5 and 5D. Among those groups only CKD stage 5 and 5D patients observed low S. testosterone and was found 39.1% and 84.0% respectively.Conclusion: Serum testosterone significantly decreased with progression of CKD stages. Positive ADAM questionnaire also found to be significant in CKD patients.J Dhaka Medical College, Vol. 26, No.1, April, 2017, Page 73-78

Sign in / Sign up

Export Citation Format

Share Document